Certara
Supports drug-development decisions with biosimulation software, scientific technology, and services.
Something off on this page? Send us feedback.
Profile
Provides biosimulation software, scientific technology, and services for drug developers from discovery through market access. Its platform combines modeling, clinical-data readiness, and cheminformatics capabilities assembled through acquisitions.
Provides biosimulation software, scientific technology, and services used in drug discovery, preclinical and clinical research, regulatory submissions, and market access. The platform grew from the combination of Tripos International and Pharsight and later added Simcyp, Pinnacle 21, and Chemaxon capabilities. Its worldwide workforce spans dozens of countries.
Modeling and simulation underpin the drug-development workflows it supports, while Pinnacle 21 addresses clinical-data fitness and submission readiness and Chemaxon serves in-silico research. The company completed the sale of its global medical-writing and related regulatory-services business in 2026, defining the current portfolio boundary.
Company facts
Key statistics
Year to date −4.3% · Average volume (30d) 3.4M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | Barclays | Reiterate | Equal Weight | $16 | $7.50 | |
| May 12, 2026 | Craig-Hallum | Reiterate | Hold | $16 | $8 | |
| Mar 6, 2026 | Barclays | Downgrade | Overweight | Equal Weight | ||
| Feb 26, 2026 | Leerink Partners | Target | $13 | $10 | ||
| Jan 6, 2026 | Leerink Partners | Upgrade | Market Perform | Outperform | $13 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | $0.09 | $0.08 | −10.4% | $98.1M | $93.3M | −4.9% | −4.65% |
| May 11, 2026Q1 FY26 | $0.11 | $0.09 | −18.2% | $106.1M | $106.9M | +0.7% | −0.78% |
| Feb 26, 2026Q4 FY25 | $0.11 | $0.09 | −18.2% | $103.1M | $103.6M | +0.5% | +4.12% |
| Nov 6, 2025Q3 FY25 | $0.11 | $0.14 | +27.3% | $103.2M | $104.6M | +1.3% | −23.07% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $106.0M | $104.6M | $104.6M | $103.6M | $106.9M | $93.3M | |
| Gross profit | $64.5M | $63.9M | $64.9M | $64.5M | $50.7M | $58.1M | |
| Operating income | $7.6M | $9.6M | $3.0M | $836.0K | $4.0M | −$196.0K | |
| Net income | $4.7M | −$2.0M | $1.5M | −$5.9M | −$8.8M | −$55.3M | |
| Diluted EPS | $0.03 | −$0.01 | $0.01 | −$0.04 | −$0.06 | −$0.36 | |
| Gross margin | 60.8% | 61.1% | 62.0% | 62.2% | 47.4% | 62.3% | |
| Operating margin | 7.2% | 9.1% | 2.9% | 0.8% | 3.7% | -0.2% |
Fiscal years (4-quarter sums)FY21 $286.1M · FY22 $335.6M · FY23 $354.3M · FY24 $385.1M · FY25 $418.8M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $184.1M · Total debt $291.8M · Total assets $1.40B · Shareholders' equity $966.5M
Dividends
No dividends on record.
Ownership
Shares outstanding 155.57M · Float 107.25M · 68.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Terry M. Mullen | 36.35M | 22.60% | 13D | Apr 14, 2025 |
| BlackRock, Inc. | 18.82M | 12.10% | 13F | Aug 7, 2026 |
| Deerfield Management Company, L.P. (Series C) | 7.51M | 4.83% | 13F | Aug 14, 2026 |
| Haveli Investment Management LLC | 7.40M | 4.76% | 13F | Aug 14, 2026 |
| Jefferies Financial Group Inc. | 7.09M | 4.56% | 13F | Aug 17, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 11, 2025 | William F. Feehery | director, officer: CHIEF EXECUTIVE OFFICER | +24,096 | $8.30 |
| Sep 9, 2025 | Leif E. Pedersen | officer: PRESIDENT, CHIEF COMMERCAL OFF | −51,224 | $10.92 |
Peers
- Simulations Plus
Biosimulation software and consulting across drug development
- ICON
Clinical research services with industry-standard pharmacometrics software
- Schrödinger
Physics-based computational platform for molecular drug discovery
- IQVIA
Technology-enabled clinical research and healthcare analytics services
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Certara | $8.35 | −0.12% | $1.30B | — | 21.5 | 3.2 | −10.8% |
| Simulations Plus | $18.40 | 0.00% | $371.9M | 46.0 | 21.6 | 4.5 | +7.5% |
| ICON | $170.02 | +0.07% | $13.02B | 39.9 | 15.2 | 1.6 | +2.3% |
| Schrödinger | $19.67 | −0.15% | $1.47B | — | — | 5.7 | +7.5% |
| IQVIA | $261.75 | +0.03% | $43.08B | 32.5 | 19.2 | 2.5 | +8.7% |
| Median | 39.9 | 19.2 | 3.5 | +7.5% |